CD274 and cancer: The blockade of PD-1/PD-L1 or CD80/PD-L1 interactions using PD-L1 inhibitors such as antibodies, peptides, and small molecules represents a promising therapeutic strategy for cancer immunotherapy [29,30,31,32,33,34,35,36].